About the Webinar
This exciting collaboration between Evotec and Professor Dirk Grimm from the University of Heidelberg will review the current challenges facing the field of gene therapy.
The webinar includes:
- A short introduction to AAV gene therapy
- Recent clinical findings
- Lessons we have already learned regarding improving AAV-based gene therapies
- Strategies for next generation canidates
- Efficacy and safety evaluation in preclinical models and their translatability into humans
About the Speakers
 |
Werner Höllriegl VP, Head of In Vivo Gene Therapy | Evotec Werner Höllriegl is heading In Vivo Gene Therapy at Evotec GT in Orth an der Donau, Austria. He received his degree in Veterinary Medicine from the University of Veterinary Medicine Vienna, Austria. After spending a couple of years as Assistant Professor at the Department of Anesthesiology, he moved into industrial research spending more than 15 years in different Pharma Companies (Baxter, AstraZeneca, Novartis Institutes for BioMedical Research, Baxalta, Shire, Takeda) in Research and Nonclinical Development, focussing on biologics and in vivo gene therapy. |
 |
Hanspeter Rottensteiner VP, Head of In Vitro Gene Therapy | Evotec Hanspeter Rottensteiner is heading In Vitro Gene Therapy at Evotec GT in Austria. Biochemist by training, Hanspeter has more than 10 years in academia, and 15 years of experience in Pharma (Baxter, Takeda) in senior positions. He brings significant expertise in drug development of biologics and gene therapies, with a strong focus on rare diseases. He received his degree in Biochemistry from the University of Vienna, Austria.
|
 |
Rüdiger Fritsch Principle Scientist, Metabolic Disease | Evotec Rüdiger Fritsch is heading a transcriptomics team at Evotec. He has recieved his PhD from the Max Planck Institute for Biophysical Chemistry. With over 15 years of experience as a biologist, Rüdiger has a strong expertise in omics.
|
 |
Dirk Grimm Professor of Viral Vector Technologies Medical Faculty and the Department of Infectious Diseases/Virology | Heidelberg University Dirk Grimm is heading the "Virus-host interactions" research group within the Department of Infectious Diseases/Virology. He has over 25 years of experience in AAV capsid and genome engineering as well as in human gene therapy. Dirk has trained under AAV experts Jürgen Kleinschmidt (German Cancer Research Center Heidelberg) and Mark Kay (Stanford University School of Medicine). |
Watch the webinar to learn more!
[hs-form id="6827abd7-94a5-4df5-8beb-3d1da436ad90" show="hide on login" url="https://news.evotecsciencepool.com/hubfs/Webinars/AAV%20GENE%20THERAPY_2022/AAV%20Gene%20Therapy%20Webinar%20WoD.mp4"]